| 초록 |
Triple-negative breast cancer (TNBC) has an aggressive phenotype with poor prognosis, but its treatment options are currently limited to the conventional chemotherapy. In order to improve its overall therapeutic outcomes, we designed a targeted therapy platform using Trop2, a recently identified cell surface glycoprotein overexpressed in 80% of TNBC patients. In particular, anti-Trop2 antibody was conjugated to polymeric nanoparticles (TNPs), composed of carboxymethyl dextran derivatives with bioreducible disulfide bonds. The release rate of encapsulated model anticancer drug, doxorubicin (DOX), from DOX-TNPs increased rapidly at the intracellular reductive environment due to the cleavage of disulfide bonds. Furthermore, DOX-TNPs were selectively taken up by Trop2-expressing TNBC cells. Overall, TNPs showed a great potential as a TNBC-targeting drug carrier. |
